Circadian Rhythm of Cardiovascular Disease: The Potential of Chronotherapy With Aspirin.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing biological mechanisms and previous studies without a systematic search or meta-analysis.
PubMed 31281821 · doi:10.3389/fcvm.2019.00084
What was done
This narrative review synthesized literature on circadian variations in cardiovascular physiology, the morning peak in platelet aggregability and cardiovascular events, and the rationale for chronotherapy with low-dose aspirin (comparing evening versus morning administration).
What was found
The abstract provides no numerical data. It reports that multiple studies show evening intake of low-dose aspirin reduces early morning platelet activity compared to morning intake. It notes that randomized trials evaluating hard clinical cardiovascular events as primary outcomes have not yet established its clinical benefit.
Why it matters
Aligning aspirin administration with circadian peaks in platelet reactivity represents a simple, low-cost strategy that could potentially lower cardiovascular event risk if verified in outcome trials.
Limits
The abstract describes a narrative review rather than a systematic review or primary trial, offering no original human data or quantitative synthesis. Existing evidence is largely limited to surrogate biochemical markers (platelet activity) rather than verified reductions in clinical cardiovascular events.
Cited by
- supports Blood pressure naturally surges and blood platelets exhibit increased stickiness in the morning as part of normal circadian biology.